| Title | Drug treatments for polycystic ovary syndrome. | | Author(s) | Radosh L | | Institution | The Reading Hospital and Medical Center, Reading, Pennsylvania 19611, USA. RadoshL@readinghospital.org | | Source | Am Fam Physician 2009 Apr 15; 79(8):671-6. | | MeSH | Contraceptives, Oral
Female
Hormone Antagonists
Humans
Hypoglycemic Agents
Polycystic Ovary Syndrome
| | Abstract | Polycystic ovary syndrome is a condition present in approximately 5 to 10 percent of women of childbearing age. Diagnosis can be difficult because the signs and symptoms can be subtle and varied. These may include hirsutism, infertility, menstrual irregularities, and biochemical abnormalities, most notably insulin resistance. Treatment should target specific manifestations and individualized patient goals. When choosing a treatment regimen, physicians must take into account comorbidities and the patient's desire for pregnancy. Lifestyle modifications should be used in addition to medical treatments for optimal results. Few agents have been approved by the U.S. Food and Drug Administration specifically for use in polycystic ovary syndrome, and several agents are contraindicated in pregnancy. Insulin-sensitizing agents are indicated for most women with polycystic ovary syndrome because they have positive effects on insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Metformin has the most data supporting its effectiveness. Rosiglitazone and pioglitazone are also effective for ameliorating hirsutism and insulin resistance. Metformin and clomiphene, alone or in combination, are first-line agents for ovulation induction. Insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine can be used in patients with hirsutism. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 19405411 |
|
